CoViproteHCt

Duración

18/4/2020 - 31/12/2021

Coordinador

Technische Universität München

Financiadores

EIT Health

The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. A significant gap is the lack of test systems to identify people already immune to SARS-CoV-2 and who would thus be protected from re-infection. While development of numerous serological assays is underway worldwide, it remains unknown whether the measured immune responses are truly protective. CoViproteHCt addresses this gap by rapidly developing and validating such urgently needed assays to characterize protective immune responses that can then be used to identify protected individuals, in particular healthcare personnel (HCP) working with COVID-19 patients and in other critical areas. The developed assays can subsequently be adapted by companies and academic partners throughout the world within weeks.
This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.

Funding

678.671 €